CDKN2A and acute lymphoblastic leukemia: Patients with CDKN2A/B deletions belonged more to the intermediate-risk groups (58.7% vs. 32.6%, p < 0.01) than patients without CDKN2A/B deletions based on CCCG-ALL 2015 risk stratification.